Professor and Chair of the Department of Ophthalmology and Director of the Stanley M. Truhlsen Eye Institute, University of Nebraska Medical Center, USA
Professor Quan Dong Nguyen currently holds the McGaw Endowed Chair in Ophthalmology and is Professor and Chair of the Department of Ophthalmology and inaugural Director of the Stanley M. Truhlsen Eye Institute at the University of Nebraska Medical Center. Professor Nguyen was previously on the faculty at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, in Baltimore, Maryland, USA.
Professor Nguyen received his baccalaureate degree from the Phillips Exeter Academy, his bachelor’s and master’s degrees from Yale University, and his medical degree from the University of Pennsylvania. He completed an internship in internal medicine at the Massachusetts General Hospital and a residency in ophthalmology at Massachusetts Eye and Ear, Harvard Medical School. Professor Nguyen also completed fellowships in immunology and uveitis at Massachusetts Eye and Ear; ocular immunology at the Wilmer Eye Institute; and medical and surgical diseases of the vitreous and retina at the Schepens Eye Research Institute and Massachusetts Eye and Ear.
Professor Nguyen is a fellow of the AAO. He has received many commendations and awards, including the National Research Service Award and R01 Award from the National Institutes of Health, the Senior Achievement Award from the AAO, the Senior Honor Award from the American Society of Retina Specialists, and the Carl Camras Translational Research Award from ARVO.
Professor Nguyen serves as principal and co-investigator on multiple clinical trials sponsored by the National Eye Institute and other organizations for macular edema (from diabetes and uveitis), neovascular AMD, and ocular inflammatory and uveitic diseases. He is known for his innovative work in early, proof-of-concept, first-in-human clinical trials to evaluate potential pharmacotherapeutic agents for retinal vascular and uveitic diseases.
Professor Nguyen has chaired the US multicenter READ-2, READ-3 and iDEAL studies, evaluating the potential role of VEGF antagonists for DME. Recently, he led his team in the design and launch of the VIDI study, assessing the role of a vascular adhesion protein-1 inhibitor for DME. Professor Nguyen is also leading the SAVE and STOP-UVEITIS studies to evaluate the role of new pharmacologic agents, including specific interleukin inhibition, in uveitis and ocular inflammatory diseases.
Most recently, Professor Nguyen has been named the inaugural Editor-in-Chief of the American Journal of Ophthalmology Case Reports. He also serves on the editorial boards of various other scientific journals.